Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors

BACKGROUND: Treatment recommendations for patients with neuroendocrine tumors (NETs) include the use of octreotide long-acting release (LAR) for long-term therapy and immediate-release (IR) as rescue therapy to control the breakthrough symptoms of carcinoid syndrome (CS). High doses of LAR are commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yue, Anthony, Lowell, Delcher, Chris, Moga, Daniela C, Chauhan, Aman, Huang, Bin, Adams, Val
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243760/
https://www.ncbi.nlm.nih.gov/pubmed/36994847
http://dx.doi.org/10.1093/oncolo/oyad057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243760/
https://www.ncbi.nlm.nih.gov/pubmed/36994847
http://dx.doi.org/10.1093/oncolo/oyad057

Ejemplares similares